<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631355</url>
  </required_header>
  <id_info>
    <org_study_id>18-00538</org_study_id>
    <nct_id>NCT03631355</nct_id>
  </id_info>
  <brief_title>Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA</brief_title>
  <official_title>Reducing Hemarthrosis in Anterior Cruciate Ligament Reconstruction With BTB Autograft by the Administration of Intravenous Tranexamic Acid: A Double-Blind Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to evaluate the effects of administering intravenous&#xD;
      tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction&#xD;
      with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and&#xD;
      post operative pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the proposed study is to evaluate the effects of administering intravenous&#xD;
      tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction&#xD;
      with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and&#xD;
      post operative pain. Patients received the standard arthroscopic ACL reconstruction with a&#xD;
      BTB autograft and were randomized to either receiving or not receiving two individual doses&#xD;
      of TXA intra-operatively or receive. The goal of the study is to determine and evaluate the&#xD;
      effect of intra-operative TXA on post-operative hemarthrosis, pain reduction, and opioid&#xD;
      consumption.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>POST-OPERATIVE HEMARTHROSIS</measure>
    <time_frame>Post-operative week 1</time_frame>
    <description>Measured by assessing the operative knee at the first post-operative visit for the need of joint aspiration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>POST-OPERATIVE Opioid Consumption</measure>
    <time_frame>Days 1-7</time_frame>
    <description>Each patient's opioid consumption was measured by morphine milligram equivalents (MME).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>POST-OPERATIVE Patient Reported Pain Score on the Visual Analog Scale (VAS)</measure>
    <time_frame>Post-operative day 7</time_frame>
    <description>Pain severity, measured by the Visual Analog Scale (VAS): a scale of 1-10, with 1 being the least amount of pain and 10 being the most amount of pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Anterior Cruciate Ligament Reconstruction</condition>
  <arm_group>
    <arm_group_label>ACL Reconstruction w/ BTB Autograft + IV TXA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACL Reconstruction w/ BTB Autograft, no IV TXA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
    <arm_group_label>ACL Reconstruction w/ BTB Autograft + IV TXA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -PATIENTS UNDERGOING AN ACL RECONSTRUCTION WITH BTB AUTOGRAFT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects,&#xD;
             dementia, etc.)&#xD;
&#xD;
          -  Younger than 18 years of age&#xD;
&#xD;
          -  Any patient considered a vulnerable subject&#xD;
&#xD;
          -  Have bleeding or clotting disorder&#xD;
&#xD;
          -  Preoperative anticoagulation therapy&#xD;
&#xD;
          -  Abnormal coagulation profile&#xD;
&#xD;
          -  Renal disorder or insufficiency&#xD;
&#xD;
          -  Sickle cell disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Alaia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <results_first_submitted>December 21, 2020</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemarthrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03631355/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ACL Reconstruction w/ BTB Autograft + IV TXA</title>
          <description>Tranexamic Acid: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
        </group>
        <group group_id="P2">
          <title>ACL Reconstruction w/ BTB Autograft, no IV TXA</title>
          <description>Received a standard ACL Reconstruction w/ BTB Autograft without IV Tranexamic Acid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACL Reconstruction w/ BTB Autograft + IV TXA</title>
          <description>Tranexamic Acid: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
        </group>
        <group group_id="B2">
          <title>ACL Reconstruction w/ BTB Autograft, no IV TXA</title>
          <description>Received a standard ACL Reconstruction w/ BTB Autograft without IV Tranexamic Acid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="5.8"/>
                    <measurement group_id="B2" value="29.7" spread="8.5"/>
                    <measurement group_id="B3" value="29.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="5.2"/>
                    <measurement group_id="B2" value="26.1" spread="5.2"/>
                    <measurement group_id="B3" value="26.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Operative Knee (Right, Left)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Operative Knee (Right)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Operative Knee (Left)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Meniscal Repair (Yes, No)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Meniscal Repair (Yes)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Meniscal Repair (No)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Meniscectomy (Yes, No)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Meniscectomy (Yes)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Meniscectomy (No)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>POST-OPERATIVE HEMARTHROSIS</title>
        <description>Measured by assessing the operative knee at the first post-operative visit for the need of joint aspiration.</description>
        <time_frame>Post-operative week 1</time_frame>
        <population>The patients in each respective arm were evaluated for knee joint hemarthrosis and prompted joint aspiration because of pain or significant swelling.</population>
        <group_list>
          <group group_id="O1">
            <title>ACL Reconstruction w/ BTB Autograft + IV TXA</title>
            <description>Tranexamic Acid: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
          </group>
          <group group_id="O2">
            <title>ACL Reconstruction w/ BTB Autograft, no IV TXA</title>
            <description>Received a standard ACL Reconstruction w/ BTB Autograft without IV Tranexamic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>POST-OPERATIVE HEMARTHROSIS</title>
          <description>Measured by assessing the operative knee at the first post-operative visit for the need of joint aspiration.</description>
          <population>The patients in each respective arm were evaluated for knee joint hemarthrosis and prompted joint aspiration because of pain or significant swelling.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="23.1"/>
                    <measurement group_id="O2" value="37.3" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>POST-OPERATIVE Opioid Consumption</title>
        <description>Each patient's opioid consumption was measured by morphine milligram equivalents (MME).</description>
        <time_frame>Days 1-7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACL Reconstruction w/ BTB Autograft + IV TXA</title>
            <description>Tranexamic Acid: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
          </group>
          <group group_id="O2">
            <title>ACL Reconstruction w/ BTB Autograft, no IV TXA</title>
            <description>Received a standard ACL Reconstruction w/ BTB Autograft without IV Tranexamic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>POST-OPERATIVE Opioid Consumption</title>
          <description>Each patient's opioid consumption was measured by morphine milligram equivalents (MME).</description>
          <units>MME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.9" spread="90.9"/>
                    <measurement group_id="O2" value="113.9" spread="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>POST-OPERATIVE Patient Reported Pain Score on the Visual Analog Scale (VAS)</title>
        <description>Pain severity, measured by the Visual Analog Scale (VAS): a scale of 1-10, with 1 being the least amount of pain and 10 being the most amount of pain.</description>
        <time_frame>Post-operative day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACL Reconstruction w/ BTB Autograft + IV TXA</title>
            <description>Tranexamic Acid: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
          </group>
          <group group_id="O2">
            <title>ACL Reconstruction w/ BTB Autograft, no IV TXA</title>
            <description>Received a standard ACL Reconstruction w/ BTB Autograft without IV Tranexamic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>POST-OPERATIVE Patient Reported Pain Score on the Visual Analog Scale (VAS)</title>
          <description>Pain severity, measured by the Visual Analog Scale (VAS): a scale of 1-10, with 1 being the least amount of pain and 10 being the most amount of pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.9"/>
                    <measurement group_id="O2" value="3.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACL Reconstruction w/ BTB Autograft + IV TXA</title>
          <description>Tranexamic Acid: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
        </group>
        <group group_id="E2">
          <title>ACL Reconstruction w/ BTB Autograft, no IV TXA</title>
          <description>Received a standard ACL Reconstruction w/ BTB Autograft without IV Tranexamic Acid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Possibility of observer bias is present as we did not perform in-office aspirations in patients in whom we thought the hemarthroses were not clinically significant, as these procedures can be painful and confer some risk of infection. Despite the decision to aspirate being made clinically, post-study analysis revealed no difference in the rate each surgeon performed an aspiration.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael J. Alaia</name_or_title>
      <organization>NYU Langone Health Orthopedic Hospital</organization>
      <phone>6465017223</phone>
      <email>michael.alaia@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

